التفاصيل البيبلوغرافية
| العنوان: |
Risk factors and outcome of COVID-19 in patients with hematological malignancies. |
| المؤلفون: |
Piñana, José Luis, Martino, Rodrigo, García-García, Irene, Parody, Rocío, Morales, María Dolores, Benzo, Gonzalo, Gómez-Catalan, Irene, Coll, Rosa, De La Fuente, Ignacio, Luna, Alejandro, Merchán, Beatriz, Chinea, Anabelle, de Miguel, Dunia, Serrano, Ana, Pérez, Carmen, Diaz, Carola, Lopez, José Luis, Saez, Adolfo Jesús, Bailen, Rebeca, Zudaire, Teresa |
| المصدر: |
Experimental Hematology & Oncology; 8/25/2020, Vol. 9 Issue 1, pN.PAG-N.PAG, 1p |
| مصطلحات موضوعية: |
HEMATOLOGIC malignancies, COVID-19, STEM cell transplantation, LOGISTIC regression analysis |
| مصطلحات جغرافية: |
SPAIN |
| مستخلص: |
Background: Prognostic factors of poor outcome in patients with hematological malignancies and COVID-19 are poorly defined. Patients and methods: This was a Spanish transplant group and cell therapy (GETH) multicenter retrospective observational study, which included a large cohort of blood cancer patients with laboratory-confirmed SARS-CoV-2 infection through PCR assays from March 1st 2020 to May 15th 2020. Results: We included 367 pediatric and adult patients with hematological malignancies, including recipients of autologous (ASCT) (n = 58) or allogeneic stem cell transplantation (allo-SCT) (n = 65) from 41 hospitals in Spain. Median age of patients was 64 years (range 1–93.8). Recipients of ASCT and allo-SCT showed lower mortality rates (17% and 18%, respectively) compared to non-SCT patients (31%) (p = 0.02). Prognostic factors identified for day 45 overall mortality (OM) by logistic regression multivariate analysis included age > 70 years [odds ratio (OR) 2.1, 95% confidence interval (CI) 1.2–3.8, p = 0.011]; uncontrolled hematological malignancy (OR 2.9, 95% CI 1.6–5.2, p < 0.0001); ECOG 3–4 (OR, 2.56, 95% CI 1.4–4.7, p = 0.003); neutropenia (< 0.5 × 109/L) (OR 2.8, 95% CI 1.3–6.1, p = 0.01); and a C-reactive protein (CRP) > 20 mg/dL (OR 3.3, 95% CI 1.7–6.4, p < 0.0001). In multivariate analysis of 216 patients with very severe COVID-19, treatment with azithromycin or low dose corticosteroids was associated with lower OM (OR 0.42, 95% CI 0.2–0.89 and OR 0.31, 95% CI 0.11–0.87, respectively, p = 0.02) whereas the use of hidroxycloroquine did not show significant improvement in OM (OR 0.64, 95% CI 0.37–1.1, P = 0.1). Conclusions: In most patients with hematological malignancies COVID-19 mortality was directly driven by older age, disease status, performance status, as well as by immune (neutropenia) parameters and level of inflammation (high CRP). Use of azithromycin and low dose corticosteroids may be of value in very severe COVID-19. [ABSTRACT FROM AUTHOR] |
|
Copyright of Experimental Hematology & Oncology is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder